G1 Therapeutics buy Wedbush
Start price
13.02.24
/
50%
€2.33
Target price
13.02.25
€3.74
Performance (%)
54.68%
Price
25.04.24
€3.60
Summary
This prediction is currently active. With a performance of 54.68% the BUY prediction by Wedbush is a big success. This prediction currently runs until 13.02.25. The prediction end date can be changed by Wedbush at any time. Wedbush has 50% into this predictionG1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| G1 Therapeutics | -5.852% | -5.852% |
| iShares Core DAX® | 2.594% | -1.861% |
| iShares Nasdaq 100 | 3.553% | -2.064% |
| iShares Nikkei 225® | 0.687% | -8.704% |
| iShares S&P 500 | 2.209% | -1.988% |
Comments by Wedbush for this prediction
In the thread G1 Therapeutics diskutieren
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its price target lowered by analysts at Wedbush from $5.00 to $4.00. They now have an "outperform" rating on the stock.
Ratings data for GTHX provided by MarketBeat